CARDINAL POINT PARTNERS for TONIX PHARMACEUTICALS, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN A WOLFE | — |
Budget/Appropriations BUD
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN A WOLFE | — |
Defense DEF
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN A WOLFE | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.